• Xudong Ma, Xueqi Ju, Juehui Shen, and Lala Zheng.
• Department of Dentistry, Huzhou University, Huzhou, China.
• Medicine (Baltimore). 2022 Dec 9; 101 (49): e31958e31958.

BackgroundThere is still a lack of credible evidence in the literature regarding the effectiveness of recombinant human bone morphogenetic protein 2 (rhBMP-2) in bone regeneration of alveolar bone defects. Therefore, the purpose of this study is to evaluate the efficacy and safety of rhBMP-2 in autogenous bone graft in bone regeneration of alveolar bone defects and to provide basis for clinical practice.MethodsAs of March 2023, two independent investigators will identify target literature by searching seven major databases (EMBASE, Google Scholar, PubMed, Cochrane Library, Wan Fang, CNKI, and Web of Science). All clinical cohort studies evaluating the efficacy of rhBMP-2 will be included. The outcomes of the study include changes in the depth of the dental pocket at the involved site, increased clinical attachment levels, patient satisfaction, and adverse events. The Cochrane risk of bias tool will be independently used to evaluate the risk of bias of included randomized cohort studies by two reviewers. A modified version of the Downs and Black tool is adopted to evaluate the quality of nonrandomized cohort studies.ResultsWe hypothesized that rhBMP-2 plays an active role in bone regeneration in alveolar bone defects.ConclusionsIt is worthy to critically review the evidence of the assessment of rhBMP-2 to inform clinical practice.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

21 keywords...

hide…